<?xml version="1.0" encoding="UTF-8" ?><!-- Generated on Wed, 29 Apr 2026 12:15:59 -0400--><rss version="2.0">
    <channel>
        <title>Immunovant, Inc. (IMVT) SEC Filings</title>
        <link>https://www.immunovant.com/investors/sec-filings/quarterly-reports/rss</link>
        <description>Immunovant, Inc. (IMVT) - Quarterly Reports</description>
        <language>en-us</language>
                                            <image>
                <url>https://d1io3yog0oux5.cloudfront.net/_d6ae8ad1fc90c30ceeec0c8ff3e3b1be/immunovant/files/theme/images/logo-sm.jpg</url>
                <title>Immunovant, Inc. Logo</title>
                <link>/investors</link>
            </image>
                <generator>Equisolve Investor Relations Suite</generator>
        
                            <item>
                <title><![CDATA[10-Q - Quarterly report [Sections 13 or 15(d)]]]></title>
                <description><![CDATA[6 Related Documents: 10-Q, EX-10.1, EX-31.1, EX-31.2, EX-32.1, EX-32.2]]></description>
                <link>https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000011/0001764013-26-000011.pdf</link>
                <pubDate>Fri, 06 Feb 26 07:24:48 -0500</pubDate>
                <guid>https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000011/0001764013-26-000011.pdf</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[10-Q - Quarterly report [Sections 13 or 15(d)]]]></title>
                <description><![CDATA[5 Related Documents: 10-Q, EX-31.1, EX-31.2, EX-32.1, EX-32.2]]></description>
                <link>https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-25-000149/0001764013-25-000149.pdf</link>
                <pubDate>Mon, 10 Nov 25 07:30:57 -0500</pubDate>
                <guid>https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-25-000149/0001764013-25-000149.pdf</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[10-Q - Quarterly report [Sections 13 or 15(d)]]]></title>
                <description><![CDATA[8 Related Documents: 10-Q, EX-10.2, EX-10.4, EX-10.5, EX-31.1, EX-31.2, EX-32.1, EX-32.2]]></description>
                <link>https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-25-000129/0001764013-25-000129.pdf</link>
                <pubDate>Mon, 11 Aug 25 07:30:25 -0400</pubDate>
                <guid>https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-25-000129/0001764013-25-000129.pdf</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[10-Q - Quarterly report pursuant to Section 13 or 15(d)]]></title>
                <description><![CDATA[6 Related Documents: 10-Q, EX-10.1, EX-31.1, EX-31.2, EX-32.1, EX-32.2]]></description>
                <link>https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-25-000026/0001764013-25-000026.pdf</link>
                <pubDate>Thu, 06 Feb 25 06:45:53 -0500</pubDate>
                <guid>https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-25-000026/0001764013-25-000026.pdf</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[10-Q - Quarterly report pursuant to Section 13 or 15(d)]]></title>
                <description><![CDATA[6 Related Documents: 10-Q, EX-10.1, EX-31.1, EX-31.2, EX-32.1, EX-32.2]]></description>
                <link>https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-24-000184/0001764013-24-000184.pdf</link>
                <pubDate>Thu, 07 Nov 24 06:50:44 -0500</pubDate>
                <guid>https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-24-000184/0001764013-24-000184.pdf</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[10-Q - Quarterly report pursuant to Section 13 or 15(d)]]></title>
                <description><![CDATA[5 Related Documents: 10-Q, EX-31.1, EX-31.2, EX-32.1, EX-32.2]]></description>
                <link>https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-24-000148/0001764013-24-000148.pdf</link>
                <pubDate>Tue, 06 Aug 24 16:32:54 -0400</pubDate>
                <guid>https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-24-000148/0001764013-24-000148.pdf</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[10-Q - Quarterly report pursuant to Section 13 or 15(d)]]></title>
                <description><![CDATA[6 Related Documents: 10-Q, EX-10.1, EX-31.1, EX-31.2, EX-32.1, EX-32.2]]></description>
                <link>https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-24-000026/0001764013-24-000026.pdf</link>
                <pubDate>Mon, 12 Feb 24 07:06:51 -0500</pubDate>
                <guid>https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-24-000026/0001764013-24-000026.pdf</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[10-Q - Quarterly report pursuant to Section 13 or 15(d)]]></title>
                <description><![CDATA[5 Related Documents: 10-Q, EX-31.1, EX-31.2, EX-32.1, EX-32.2]]></description>
                <link>https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-23-000133/0001764013-23-000133.pdf</link>
                <pubDate>Thu, 09 Nov 23 07:14:02 -0500</pubDate>
                <guid>https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-23-000133/0001764013-23-000133.pdf</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[10-Q - Quarterly report pursuant to Section 13 or 15(d)]]></title>
                <description><![CDATA[5 Related Documents: 10-Q, EX-31.1, EX-31.2, EX-32.1, EX-32.2]]></description>
                <link>https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-23-000092/0001764013-23-000092.pdf</link>
                <pubDate>Thu, 10 Aug 23 07:19:57 -0400</pubDate>
                <guid>https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-23-000092/0001764013-23-000092.pdf</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[10-Q - Quarterly report pursuant to Section 13 or 15(d)]]></title>
                <description><![CDATA[11 Related Documents: 10-Q, EX-10.1, EX-10.2, EX-10.3, EX-10.4, EX-10.5, EX-10.6, EX-31.1, EX-31.2, EX-32.1, EX-32.2]]></description>
                <link>https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-23-000022/0001764013-23-000022.pdf</link>
                <pubDate>Fri, 03 Feb 23 07:18:04 -0500</pubDate>
                <guid>https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-23-000022/0001764013-23-000022.pdf</guid>
                                                                            </item>
            </channel>
</rss>